FDA questions hypoglycemia risk for Novo Nordisk's once-weekly insulin ahead of adcomm
The FDA is raising concerns about increased rates of hypoglycemia following treatment with Novo Nordisk’s experimental once-weekly basal insulin ahead of an advisory committee meeting …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
